Related Experiment Video
Updated: Jan 21, 2026
08:11
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
11.5K
Pediatric Neurology Workforce in Canada: A 5-Year Update
Lauren E Strasser1, Serena L Orr2, Hugh J McMillan3
1McMaster University, Hamilton, Ontario, Canada.
Summary
The Canadian pediatric neurology workforce has grown significantly, yet wait times remain long and access is uneven. Projections indicate continued growth, with no anticipated underemployment issues in the coming decade.
Area of Science:
- Neurology
- Healthcare Workforce Analysis
- Pediatric Medicine
Background:
- A 2013 task force recommended continued surveillance of the Canadian pediatric neurology workforce.
- Previous consensus indicated no need to reduce training positions but highlighted the need for ongoing monitoring.
Purpose of the Study:
- To provide a 5-year update on Canadian pediatric neurology workforce data.
- To analyze current trends and project future workforce needs.
Main Methods:
- Collected data on practicing pediatric neurologists in Canada, including practice types and certification dates.
- Utilized international data for comparative analysis and national datasets for residency positions and graduate numbers.
- Developed future projection models based on population data and historical trends.
Main Results:
- The number of pediatric neurologists in Canada increased by 165% since 1994, but wait times have not improved.
- Significant regional disparities in access to child neurologists exist.
- The Canadian workforce for outpatient consultations is smaller proportionally than in the USA, with a net addition of 4.9 neurologists annually, projecting 200 by 2033.
Conclusions:
- Despite workforce expansion over two decades, underemployment is not predicted for Canadian pediatric neurologists in the next ten years.
Related Concept Videos
01:045-Number Summary
5.5K
In a dataset, the 5-number summary includes the minimum data value, the data value of the first quartile, the median data value or data value of the second quartile, the data value of the third quartile, and the maximum data value. These 5 data values can be visualized as a box and whisker plot.
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
5.5K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
263
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
263
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
196
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
257
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
257
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
608
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
608